Integra Lifesciences Holdings Corp (IART) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Integra Lifesciences Holdings Corp
Ticker: IART CIK: 917520

EXHIBIT 99.1

News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III Investor Relations:

Corporate Vice President, Angela Steinway

Finance and Administration, (609) 936-2268

and Chief Financial Officer

(609) 275-0500 angela.steinway@integralife.com

Integra LifeSciences Reports Fourth Quarter 2013 Financial Results

Increases Fourth Quarter Revenues 3% to $221 Million

Introduces 2014 Full-Year Guidance

Plainsboro, New Jersey, February 25, 2014 -

Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the fourth quarter ending December 31, 2013. Total revenues for the fourth quarter were $220.8 million, reflecting an increase of $6.3 million, or 3.0%, over the fourth quarter of 2012. Total revenues in the full year of 2013 were $836.2 million, reflecting an increase of $5.3 million, or 0.6%, over 2012.

Excluding the contribution of revenues from discontinued products, revenues increased 3.5% over the fourth quarter of 2012 and 1.2% over the full year 2012. Currency had a negligible impact on revenues in both the quarter and full year periods.

The Company reported GAAP net income of $12.2 million, or $0.40 per diluted share, for the fourth quarter of 2013, compared to GAAP net income of $12.8 million, or $0.46 per diluted share, for the fourth quarter of 2012. The Company reported GAAP net loss of $(17.0) million, or $(0.60) per diluted share, for the full year 2013, compared to GAAP net income of $41.2 million, or $1.44 per diluted share in 2012.

Net income for the fourth quarter of 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $23.8 million, or $0.78 per diluted share, compared to adjusted net income of $22.0 million, or $0.78 per diluted share, in the fourth quarter of 2012. Adjusted net income for the full year 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $70.6 million, or $2.45 per diluted share, compared to $87.2 million, or $3.06 per diluted share in 2012.

“Our organization overcame significant challenges in 2013, and I am excited about the opportunities ahead,” said Peter Arduini, President and Chief Executive Officer. “Our quality and operations teams are strengthened and stabilized, and our commercial teams are launching significant new products, including DuraSeal(R) product lines and our Titan(TM) Shoulder System. We look forward to making further headway on our strategic optimization and growth objectives in 2014.”

Integra generated $11.7 million of cash flows from operations and invested $10.1 million in capital expenditures in the fourth quarter of 2013. For the full year ended December 31, 2013, Integra's cash flows from operations totaled $53.3 million and cash invested in capital expenditures was $47.9 million.

Adjusted EBITDA for the fourth quarter of 2013 was $43.1 million, an increase from $40.7 million in the fourth quarter of the prior year. Adjusted EBITDA excluding stock-based compensation for the fourth quarter of 2013 was $45.9 million, an increase from $43.1 million in the fourth quarter of the prior year. Adjusted EBITDA for the full year 2013 was $138.9 million, a decrease of 16.5% compared to the prior year. Adjusted EBITDA excluding stock-based compensation for the full year 2013 was $149.3 million, a decrease of 14.9% compared to the prior year.

The following information was filed by Integra Lifesciences Holdings Corp (IART) on Tuesday, February 25, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Integra Lifesciences Holdings Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Integra Lifesciences Holdings Corp.

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/917520/000091752014000007/iart-20131231x10k.htm